Joanna M Sturtevant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joanna M Sturtevant has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- David Wayne Johnson
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia
3 shared publications - Carmel Mary Hawley
Australasian Kidney Trials Network (AKTN), The University of Queensland, Brisbane, Queensland, Australia
2 shared publications Andrew Bofinger
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
1 shared publication- Carolyn L van Eps
Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia
1 shared publication Chin Soon Ng
Department of Clinical Pharmacology
1 shared publication- David William Mudge
University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia
1 shared publication
Latest Publications
- Open Access
- 28 July 2009
- Published by Springer Nature in BMC Nephrology
- Vol. 10 (1) , 20
Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)
Background: The main hypothesis of this study is that oral heme iron polypeptide (HIP; Proferrin®ES) administration will more effectively augment iron stores in erythropoietic stimulatory agent (ESA)-treated peritoneal dialysis (PD) patients than conventional oral iron supplementation (Ferrogradumet®).Methods: Inclusion criteria are peritoneal dialysis patients treated with darbepoietin alpha (DPO; Aranesp®, Amgen) for ≥ 1 month. Patients will be randomized 1:1 to receive either slow-release ferrous sulphate (1 tablet twice daily; control) or HIP (1 tablet twice daily) for a period of 6 months. The study will follow an open-label design but outcome assessors will be blinded to study treatment. During the 6-month study period, haemoglobin levels will be measured monthly and iron studies (including transferring saturation [TSAT] measurements) will be performed bi-monthly. The primary outcome measure will be the difference in TSAT levels between the 2 groups at the end of the 6 month study period, adjusted for baseline values using analysis of covariance (ANCOVA). Secondary outcome measures will include serum ferritin concentration, haemoglobin level, DPO dosage, Key's index (DPO dosage divided by haemoglobin concentration), and occurrence of adverse events (especially gastrointestinal adverse events).Discussion: This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their peritoneal dialysis patients determine whether HIP administration more effectively augments iron stores in ESP-treated PD patients than conventional oral iron supplementation.Trial Registration: Australia New Zealand Clinical Trials Registry number ACTRN12609000432213.
- 28 July 2009
- Published by Springer Nature in BMC Nephrology
- Vol. 10 (1) , 20
Open AccessRationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)
Background: The main hypothesis of this study is that oral heme iron polypeptide (HIP; Proferrin®ES) administration will more effectively augment iron stores in erythropoietic stimulatory agent (ESA)-treated peritoneal dialysis (PD) patients than conventional oral iron supplementation (Ferrogradumet®).Methods: Inclusion criteria are peritoneal dialysis patients treated with darbepoietin alpha (DPO; Aranesp®, Amgen) for ≥ 1 month. Patients will be randomized 1:1 to receive either slow-release ferrous sulphate (1 tablet twice daily; control) or HIP (1 tablet twice daily) for a period of 6 months. The study will follow an open-label design but outcome assessors will be blinded to study treatment. During the 6-month study period, haemoglobin levels will be measured monthly and iron studies (including transferring saturation [TSAT] measurements) will be performed bi-monthly. The primary outcome measure will be the difference in TSAT levels between the 2 groups at the end of the 6 month study period, adjusted for baseline values using analysis of covariance (ANCOVA). Secondary outcome measures will include serum ferritin concentration, haemoglobin level, DPO dosage, Key's index (DPO dosage divided by haemoglobin concentration), and occurrence of adverse events (especially gastrointestinal adverse events).Discussion: This investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their peritoneal dialysis patients determine whether HIP administration more effectively augments iron stores in ESP-treated PD patients than conventional oral iron supplementation.Trial Registration: Australia New Zealand Clinical Trials Registry number ACTRN12609000432213.
- 1 December 2008
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 38 (4) , 280-282
Acute Renal Failure in Patients on Diuretics and/or NSAID, COX-2 inhibitors, ACEI, ARA
- 1 December 2008
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 38 (4) , 280-282
Acute Renal Failure in Patients on Diuretics and/or NSAID, COX-2 inhibitors, ACEI, ARA
- 22 December 2004
- Published by Wiley in Nephrology
- Vol. 9 (6) , 406-413
Efficacy and side‐effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders
SUMMARY: Background: Poor phosphate control is common among patients with end‐stage renal disease. Sevelamer hydrochloride has been demonstrated to be a safe and effective phosphate binder when used as a monotherapy. However, cost limits its usefulness in many countries. Data assessing its effectiveness and safety in combination with conventional phosphate binders are lacking.Methods: Dialysis patients meeting the following inclusion criteria participated in this study: (i) hyperphosphataemia >1.8 mmol/L (5.6 mg/dL); and (ii) an inability to tolerate currently available binders. The trial was conducted in three phases each lasting 3 months: (i) an observation phase (patients continued on their regular phosphate binders); (ii) a titration phase (sevelamer was added at a dose of 403 mg three times daily with meals, titrated to a maximum of 1209 mg three times daily); and (iii) a maintenance phase.Results: Twenty‐five patients were recruited into the study. Eighteen patients completed all three trial phases. Mean serum phosphate dropped from 2.11 ± 0.06 mmol/L (6.6 ± 0.2 mg/dL) during the observation period to 1.91 ± 0.01 mmol/L (5.9 ± 0.003 mg/dL) during the maintenance phase (P = 0.02). Calcium × phosphate product fell from 5.49 ± 0.17 mmol2/L2 (68.64 ± 2.11 mg2 dL2) to 4.89 ± 0.27 mmol2/L2 (61.36 ± 3.35 mg2 dL2) (P = 0.02). There was no significant change in serum calcium or parathyroid hormone. Total serum cholesterol fell from 3.8 mmol/L (3.4–4.37) 147 mg/dL (131–169) to 3.55 mmol/L (2.97–4.2) 137 mg/dL (115–162) (P = 0.02). Serum low‐density lipoprotein cholesterol also fell significantly from 1.67 ± 0.10 mmol/L (65 ± 4 mg/dL) to 1.52 ± 0.11 mmol/L (59 ± 4 mg/dL) (P = 0.04). The average prescribed dose of sevelamer was 2.4 g/day. Elemental calcium dropped from 3.4 g/day (1.4 to 4.6) to 1.2 g/day (0.6–2.4) (P = 0.04). Seventy‐two per cent of patients reported mild flatulence, nausea and indigestion. Three patients discontinued treatment because of adverse effects.Conclusions: Sevelamer in combination with conventional phosphate binders is effective in lowering serum phosphate and calcium‐phosphate product in patients with refractory hyperphosphataemia. Beneficial effects on lipid profile were also observed. Mild gastrointestinal upset is common.
- 22 December 2004
- Published by Wiley in Nephrology
- Vol. 9 (6) , 406-413
Efficacy and side‐effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders
SUMMARY: Background: Poor phosphate control is common among patients with end‐stage renal disease. Sevelamer hydrochloride has been demonstrated to be a safe and effective phosphate binder when used as a monotherapy. However, cost limits its usefulness in many countries. Data assessing its effectiveness and safety in combination with conventional phosphate binders are lacking.Methods: Dialysis patients meeting the following inclusion criteria participated in this study: (i) hyperphosphataemia >1.8 mmol/L (5.6 mg/dL); and (ii) an inability to tolerate currently available binders. The trial was conducted in three phases each lasting 3 months: (i) an observation phase (patients continued on their regular phosphate binders); (ii) a titration phase (sevelamer was added at a dose of 403 mg three times daily with meals, titrated to a maximum of 1209 mg three times daily); and (iii) a maintenance phase.Results: Twenty‐five patients were recruited into the study. Eighteen patients completed all three trial phases. Mean serum phosphate dropped from 2.11 ± 0.06 mmol/L (6.6 ± 0.2 mg/dL) during the observation period to 1.91 ± 0.01 mmol/L (5.9 ± 0.003 mg/dL) during the maintenance phase (P = 0.02). Calcium × phosphate product fell from 5.49 ± 0.17 mmol2/L2 (68.64 ± 2.11 mg2 dL2) to 4.89 ± 0.27 mmol2/L2 (61.36 ± 3.35 mg2 dL2) (P = 0.02). There was no significant change in serum calcium or parathyroid hormone. Total serum cholesterol fell from 3.8 mmol/L (3.4–4.37) 147 mg/dL (131–169) to 3.55 mmol/L (2.97–4.2) 137 mg/dL (115–162) (P = 0.02). Serum low‐density lipoprotein cholesterol also fell significantly from 1.67 ± 0.10 mmol/L (65 ± 4 mg/dL) to 1.52 ± 0.11 mmol/L (59 ± 4 mg/dL) (P = 0.04). The average prescribed dose of sevelamer was 2.4 g/day. Elemental calcium dropped from 3.4 g/day (1.4 to 4.6) to 1.2 g/day (0.6–2.4) (P = 0.04). Seventy‐two per cent of patients reported mild flatulence, nausea and indigestion. Three patients discontinued treatment because of adverse effects.Conclusions: Sevelamer in combination with conventional phosphate binders is effective in lowering serum phosphate and calcium‐phosphate product in patients with refractory hyperphosphataemia. Beneficial effects on lipid profile were also observed. Mild gastrointestinal upset is common.